Patients with high body weight are at increased risk of developing atrial fibrillation (AF) or
venous thromboembolism (VTE) and are often treated with antithrombotic drugs. 1 Direct …

Background Direct‐acting oral anticoagulants are now the preferred method of
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …

BACKGROUND/OBJECTIVE Direct‐acting oral anticoagulants (DOACs) are increasingly
used to prevent or treat thromboembolism. We conducted a study to compare how well initial …

The evidence of direct oral anticoagulants (DOACs) usage for venous thromboembolism
(VTE) in patients at extremes of body weight or mass index is limited. In such situations …

Background Recently published studies indicated a high proportion of patients taking direct
oral anticoagulants (DOACs) are off-label under-or overdosed. The present study aimed at …

Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …

Background: Beginning in 2012, direct oral anticoagulants (DOACs) were approved for
treatment and prevention of venous thromboembolism. Prior investigations have …

The prevalence of both atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin
K antagonist oral anticoagulants (NOACs) have been shown to be more effective and safer …

Background Considering that the current fixed dose of direct oral anticoagulants (DOACs)
might have insufficient anticoagulation effect for overweight patients, the aim of this study …

The present study aimed to assess the associations between dosing of DOACs and
outcomes in patients with non-valvular atrial fibrillation (NVAF). Direct oral anticoagulants …